Spinocerebellar engeneration with parkinsonian features: A clinical and pathological report

Weir, Roger; Fan, Kuang Jaw

doi:10.1002/ana.410090118

Cited by 7 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3,4,5 PD patients enjoy good access to LD in Spain. While some Parkinson-plus syndromes and post-encephalitic Parkinsonism may respond to LD, 6,7,8 LD is indicated, apart from Parkinson's disease, for infrequent disorders such as restless legs syndrome. Epidemiological assessment of levodopa use (LDU) may thus be relevant for evaluation of the quality of care of PD patients and planning of community-based PD intervention strategies.…”

Section: Introductionmentioning

confidence: 99%

Epidemiological assessment of levodopa use in Spain, 1990–1995. Persistent, low consumption in the south

Cuadrado,

De Pedro‐Cuesta,

Abraira

et al. 1999

Pharmacoepidem. Drug Safe.

View full text Add to dashboard Cite

Parkinson's disease (PD) is considerably underdiagnosed in Spain and its treatment relies mainly on levodopa (LD), a drug enjoying good access country-wide. In order to identify regions with the highest potential for improvement in the quality of life of PD patients, we evaluated total sales of levodopa in Spanish provinces during the period 1990±1995, using a reported method. Total annual crude sales in the country were medium±low and increased with time. When adjusted for age and infant mortality rates (IMRs), taken as an index of socio-sanitary development, annual LD sales become stable and similar to those in the reference population, Sweden 1994. Provincial LD use (LDU) showed a wide variation in annual levels and time trends, with a north±south gradient in evidence. Statistically signi®cant clustering was seen, with the lowest crude age-adjusted and age-and IMR-adjusted LD sales in the south-west and moderately high levels in north-central and north-west provinces. The results show that LDU in Spain is medium±low, and that demographic and social factors may underlie geographical dierences in LD sales. The remarkably low LDU in selected provinces in the south-west of the country might re¯ect de®cient PD detection and/or treatment amenable to control.

show abstract

Section: Introductionmentioning

confidence: 99%

Epidemiological assessment of levodopa use in Spain, 1990–1995. Persistent, low consumption in the south

Cuadrado,

De Pedro‐Cuesta,

Abraira

et al. 1999

Pharmacoepidem. Drug Safe.

View full text Add to dashboard Cite

show abstract

Epidemiological assessment of levodopa use in Spain, 1990-1995. Persistent, low consumption in the south

Cuadrado

Pedro‐Cuesta

Abraira³

et al. 1999

Pharmacoepidem. Drug Safe.

View full text Add to dashboard Cite

Parkinson's disease (PD) is considerably underdiagnosed in Spain and its treatment relies mainly on levodopa (LD), a drug enjoying good access country‐wide. In order to identify regions with the highest potential for improvement in the quality of life of PD patients, we evaluated total sales of levodopa in Spanish provinces during the period 1990–1995, using a reported method. Total annual crude sales in the country were medium–low and increased with time. When adjusted for age and infant mortality rates (IMRs), taken as an index of socio‐sanitary development, annual LD sales become stable and similar to those in the reference population, Sweden 1994. Provincial LD use (LDU) showed a wide variation in annual levels and time trends, with a north–south gradient in evidence. Statistically significant clustering was seen, with the lowest crude age‐adjusted and age‐ and IMR‐adjusted LD sales in the south‐west and moderately high levels in north‐central and north‐west provinces. The results show that LDU in Spain is medium–low, and that demographic and social factors may underlie geographical differences in LD sales. The remarkably low LDU in selected provinces in the south‐west of the country might reflect deficient PD detection and/or treatment amenable to control. Copyright © 1999 John Wiley & Sons, Ltd.

show abstract

The Pharmacology of Levodopa in Treatment of Parkinson’s Disease: An Update

LeWitt¹

1989

Handbook of Experimental Pharmacology

View full text Add to dashboard Cite

Spinocerebellar engeneration with parkinsonian features: A clinical and pathological report

Cited by 7 publications

References 3 publications

Epidemiological assessment of levodopa use in Spain, 1990–1995. Persistent, low consumption in the south

Epidemiological assessment of levodopa use in Spain, 1990–1995. Persistent, low consumption in the south

Epidemiological assessment of levodopa use in Spain, 1990-1995. Persistent, low consumption in the south

The Pharmacology of Levodopa in Treatment of Parkinson’s Disease: An Update

Contact Info

Product

Resources

About